Transcutaneous Bilirubinometry and Phototherapy

Launched by PRINCESS AMALIA CHILDREN'S CLINIC · Jan 26, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new method for measuring bilirubin levels in newborns with a condition called neonatal hyperbilirubinemia, which is when there is too much bilirubin in the blood. Bilirubin is a substance produced when the body breaks down red blood cells. In this study, researchers want to compare two ways of measuring bilirubin: one is a simple skin test called transcutaneous bilirubinometry, and the other is the traditional method that involves taking a blood sample. The goal is to see if the skin test can provide accurate results without needing to draw blood, which can be uncomfortable for babies.

To be eligible for this trial, newborns must be between 0 and 14 days old and need treatment with phototherapy, a special light therapy used to lower bilirubin levels. However, babies with certain skin conditions or those who have had a specific blood procedure called exchange transfusion cannot participate. If eligible, participants can expect to be assigned randomly to either the skin test group or the blood test group. This trial is currently not recruiting participants, but it aims to improve how healthcare providers monitor bilirubin levels in newborns, making the process easier and more comfortable for babies and their families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Neonates with indication for phototherapy for treatment of hyperbilirubinemia
• Exclusion Criteria:
• • skinlesions located on the sternum interfering with transcutaneous measurement
• • exchange transfusion